Skip to main content

Drug Interactions between ponesimod and Trihibit

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

tetanus toxoid ponesimod

Applies to: Trihibit (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) and ponesimod

ADJUST DOSING INTERVAL: The administration of inactivated, killed, or otherwise noninfectious vaccines during ponesimod therapy is generally safe but may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to one to two weeks after discontinuation of ponesimod therapy.

MANAGEMENT: Immune response to vaccines may be reduced during and for up to one to two weeks after discontinuation of ponesimod therapy. Treatment with ponesimod should be paused 1 week prior to and for 4 weeks after a planned vaccination to allow the full effect of vaccination to occur.

References (1)
  1. (2021) "Product Information. Ponvory (ponesimod)." Janssen Pharmaceuticals
Moderate

diphtheria toxoid ponesimod

Applies to: Trihibit (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) and ponesimod

ADJUST DOSING INTERVAL: The administration of inactivated, killed, or otherwise noninfectious vaccines during ponesimod therapy is generally safe but may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to one to two weeks after discontinuation of ponesimod therapy.

MANAGEMENT: Immune response to vaccines may be reduced during and for up to one to two weeks after discontinuation of ponesimod therapy. Treatment with ponesimod should be paused 1 week prior to and for 4 weeks after a planned vaccination to allow the full effect of vaccination to occur.

References (1)
  1. (2021) "Product Information. Ponvory (ponesimod)." Janssen Pharmaceuticals
Moderate

pertussis, acellular ponesimod

Applies to: Trihibit (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) and ponesimod

ADJUST DOSING INTERVAL: The administration of inactivated, killed, or otherwise noninfectious vaccines during ponesimod therapy is generally safe but may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to one to two weeks after discontinuation of ponesimod therapy.

MANAGEMENT: Immune response to vaccines may be reduced during and for up to one to two weeks after discontinuation of ponesimod therapy. Treatment with ponesimod should be paused 1 week prior to and for 4 weeks after a planned vaccination to allow the full effect of vaccination to occur.

References (1)
  1. (2021) "Product Information. Ponvory (ponesimod)." Janssen Pharmaceuticals
Moderate

haemophilus b conjugate (PRP-T) vaccine ponesimod

Applies to: Trihibit (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) and ponesimod

ADJUST DOSING INTERVAL: The administration of inactivated, killed, or otherwise noninfectious vaccines during ponesimod therapy is generally safe but may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to one to two weeks after discontinuation of ponesimod therapy.

MANAGEMENT: Immune response to vaccines may be reduced during and for up to one to two weeks after discontinuation of ponesimod therapy. Treatment with ponesimod should be paused 1 week prior to and for 4 weeks after a planned vaccination to allow the full effect of vaccination to occur.

References (1)
  1. (2021) "Product Information. Ponvory (ponesimod)." Janssen Pharmaceuticals

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer